Niemann-Pick Disease: Lipid Storage Disorders and Neurological Complications
Niemann-Pick disease (NPD) encompasses a group of autosomal recessive lipid storage
disorders arising from defective lysosomal acid sphingomyelinase (ASM) enzyme function,
impacting sphingomyelin metabolism and intracellular trafficking. Two major forms exist -
types A and B - distinguished by age of onset and visceral/neurological involvement severity.
Type A presents in infancy as a rapidly progressive, fatal neurological phenotype affecting
the lungs, liver and spleen. Type B has later childhood or adult onset with variable
progression.
Both arise from impaired sphingolipid catabolism building up in lysosomes. However,
mechanisms linking storage defects to tissue-specific manifestations remain unclear. While
hematopoietic stem cell transplantation shows potential benefits for Type B, no curative
treatments exist. This review surveys sphingomyelin biology, clinical features of NPD types,
the ASM gene/protein defective across subtypes, current management strategies and
emerging therapies targeting neurodegeneration outcomes through enzyme supplementation
or gene therapy aiming to reduce storage and clear accumulated substrates.
Sphingolipid Metabolism and Function
Sphingolipids including sphingomyelin represent an essential class of membrane
glycerophospholipids regulated by lysosomal catabolism:
- Biosynthesis involves serine palmitoyltransferase generating sphingoid long-chain bases,
followed by acylation to dihydroceramide then ceramide/sphingomyelin synthesis.
- Key sphingolipids act as second messengers/signaling molecules regulating proliferation,
apoptosis and autophagy through ceramide/sphingosine-1-phosphate rheostasis.
- Lysosomal ceramidase and acid sphingomyelinase hydrolyze complex sphingolipids,
ceramide and sphingomyelin for normal turnover.
- Sphingomyelin composes ~15% of brain myelin sheaths regulating neuronal integrity,
highlighting neurodegeneration consequences in NPD.
Defective ASM or redundancy pathways impairing substrate catabolism lead to storage,
compromising membrane organization and signaling networks driving disease
pathophysiology.
Clinical Features of NPD
Specific clinical features depend on neuron involvement severity:
NPD Type A
- Macrocrania, hepatosplenomegaly, vomiting, failure to thrive in infants.
- Rapidly progressive neurodegeneration, seizures, dysphagia and death by ages 2-3 without
transplantation.
NPD Type B
- Hepatosplenomegaly, vomiting initially, then varied outcomes.
- Late onset neurological signs - ataxia, dysarthria, seizures, dementia.
- Non-neurological signs - pulmonary disease, bone abnormalities.
Niemann-Pick C (NPC) Disorders
- Variable and multisystemic features based onNPC1/NPC2 gene defects.
- Hepatosplenomegaly, neurological findings, pulmonary/endocrine involvement.
Overall, brain macrophages/microglia accumulate sphingomyelin leading to
neurodegeneration severity differences dependent upon precise variants and residual enzyme
activity levels.
Genetics of NPD
All forms arise from defects in ASM (SMPD1), which encodes the lysosomal acid
sphingomyelinase enzyme:
- NPD Type A/B - Biallelic loss-of-function mutations in SMPD1 preventing sufficient ASM
levels.
- NPD Type A pseudo-deficiency - Homozygosity for splicing or missense variants
conferring residual activity.
Genotype-phenotype correlations link residual ASM amounts to severity, though variants
may not fully predict outcomes. Heterozygotes usually show no signs. Carrier testing of
relatives assesses risks.
Diagnosis
Typically based upon:
- Clinical suspicion from hepatosplenomegaly, neurological deterioration, bone
abnormalities.
- Enzyme activity assays on leukocytes/fibroblasts confirming <5% ASM activity.
- Genetic testing identifies biallelic SMPD1 variants establishing molecular diagnosis.
- MRI/CT reveals hepatic/spleen enlargement, brain atrophy in neurological cases.
- Sphingomyelin accumulation on tissue biopsy visualized histologically via filipin staining.
Early diagnosis guides screening family members and developing newborn screening
algorithms. Differential diagnosis excludes Gaucher’s disease.
Disease Management
No cure exists; care focuses reducing complications:
- Supportive care addresses pneumonias, poor nutrition in Type A.
- Seizure control utilizes anticonvulsants addressing neurological deterioration.
- Symptomatic care manages bone pain, movement disorders.
- Hematopoietic stem cell transplantation shows potential benefits for Type B.
- Substrate reduction therapies addressGSL storage defects in NPC variants.
- Enzyme replacement trials evaluate ASM supplementation or gene therapy concepts in
animal models.
Future perspectives
Progress targets neuroprotection through tailoring hematopoietic cell therapies, AAV-
delivered gene therapies replacing deficient ASM more broadly or addressing storage directly
through substrate inhibitors pending results from ongoing preclinical/clinical studies seeking
disease-modifying capabilities across NPD subtypes. Multi ‘omics may elucidate lysosomal
pathways amenable to modulation. Palliative symptom management still plays an essential
role in quality of life optimization.
Niemann-Pick disease (NPD) encompasses a group of autosomal recessive lipid storage
disorders arising from defective lysosomal acid sphingomyelinase (ASM) enzyme function,
impacting sphingomyelin metabolism and intracellular trafficking. Two major forms exist -
types A and B - distinguished by age of onset and visceral/neurological involvement severity.
Type A presents in infancy as a rapidly progressive, fatal neurological phenotype affecting
the lungs, liver and spleen. Type B has later childhood or adult onset with variable
progression.
Both arise from impaired sphingolipid catabolism building up in lysosomes. However,
mechanisms linking storage defects to tissue-specific manifestations remain unclear. While
hematopoietic stem cell transplantation shows potential benefits for Type B, no curative
treatments exist. This review surveys sphingomyelin biology, clinical features of NPD types,
the ASM gene/protein defective across subtypes, current management strategies and
emerging therapies targeting neurodegeneration outcomes through enzyme supplementation
or gene therapy aiming to reduce storage and clear accumulated substrates.
Sphingolipid Metabolism and Function
Sphingolipids including sphingomyelin represent an essential class of membrane
glycerophospholipids regulated by lysosomal catabolism:
- Biosynthesis involves serine palmitoyltransferase generating sphingoid long-chain bases,
followed by acylation to dihydroceramide then ceramide/sphingomyelin synthesis.
- Key sphingolipids act as second messengers/signaling molecules regulating proliferation,
apoptosis and autophagy through ceramide/sphingosine-1-phosphate rheostasis.
- Lysosomal ceramidase and acid sphingomyelinase hydrolyze complex sphingolipids,
ceramide and sphingomyelin for normal turnover.
- Sphingomyelin composes ~15% of brain myelin sheaths regulating neuronal integrity,
highlighting neurodegeneration consequences in NPD.
Defective ASM or redundancy pathways impairing substrate catabolism lead to storage,
compromising membrane organization and signaling networks driving disease
pathophysiology.
Clinical Features of NPD
Specific clinical features depend on neuron involvement severity:
NPD Type A
- Macrocrania, hepatosplenomegaly, vomiting, failure to thrive in infants.
- Rapidly progressive neurodegeneration, seizures, dysphagia and death by ages 2-3 without
transplantation.
NPD Type B
- Hepatosplenomegaly, vomiting initially, then varied outcomes.
- Late onset neurological signs - ataxia, dysarthria, seizures, dementia.
- Non-neurological signs - pulmonary disease, bone abnormalities.
Niemann-Pick C (NPC) Disorders
- Variable and multisystemic features based onNPC1/NPC2 gene defects.
- Hepatosplenomegaly, neurological findings, pulmonary/endocrine involvement.
Overall, brain macrophages/microglia accumulate sphingomyelin leading to
neurodegeneration severity differences dependent upon precise variants and residual enzyme
activity levels.
Genetics of NPD
All forms arise from defects in ASM (SMPD1), which encodes the lysosomal acid
sphingomyelinase enzyme:
- NPD Type A/B - Biallelic loss-of-function mutations in SMPD1 preventing sufficient ASM
levels.
- NPD Type A pseudo-deficiency - Homozygosity for splicing or missense variants
conferring residual activity.
Genotype-phenotype correlations link residual ASM amounts to severity, though variants
may not fully predict outcomes. Heterozygotes usually show no signs. Carrier testing of
relatives assesses risks.
Diagnosis
Typically based upon:
- Clinical suspicion from hepatosplenomegaly, neurological deterioration, bone
abnormalities.
- Enzyme activity assays on leukocytes/fibroblasts confirming <5% ASM activity.
- Genetic testing identifies biallelic SMPD1 variants establishing molecular diagnosis.
- MRI/CT reveals hepatic/spleen enlargement, brain atrophy in neurological cases.
- Sphingomyelin accumulation on tissue biopsy visualized histologically via filipin staining.
Early diagnosis guides screening family members and developing newborn screening
algorithms. Differential diagnosis excludes Gaucher’s disease.
Disease Management
No cure exists; care focuses reducing complications:
- Supportive care addresses pneumonias, poor nutrition in Type A.
- Seizure control utilizes anticonvulsants addressing neurological deterioration.
- Symptomatic care manages bone pain, movement disorders.
- Hematopoietic stem cell transplantation shows potential benefits for Type B.
- Substrate reduction therapies addressGSL storage defects in NPC variants.
- Enzyme replacement trials evaluate ASM supplementation or gene therapy concepts in
animal models.
Future perspectives
Progress targets neuroprotection through tailoring hematopoietic cell therapies, AAV-
delivered gene therapies replacing deficient ASM more broadly or addressing storage directly
through substrate inhibitors pending results from ongoing preclinical/clinical studies seeking
disease-modifying capabilities across NPD subtypes. Multi ‘omics may elucidate lysosomal
pathways amenable to modulation. Palliative symptom management still plays an essential
role in quality of life optimization.
Niemann-Pick disease (NPD) encompasses a group of autosomal recessive lipid storage
disorders arising from defective lysosomal acid sphingomyelinase (ASM) enzyme function,
impacting sphingomyelin metabolism and intracellular trafficking. Two major forms exist -
types A and B - distinguished by age of onset and visceral/neurological involvement severity.
Type A presents in infancy as a rapidly progressive, fatal neurological phenotype affecting
the lungs, liver and spleen. Type B has later childhood or adult onset with variable
progression.
Both arise from impaired sphingolipid catabolism building up in lysosomes. However,
mechanisms linking storage defects to tissue-specific manifestations remain unclear. While
hematopoietic stem cell transplantation shows potential benefits for Type B, no curative
treatments exist. This review surveys sphingomyelin biology, clinical features of NPD types,
the ASM gene/protein defective across subtypes, current management strategies and
emerging therapies targeting neurodegeneration outcomes through enzyme supplementation
or gene therapy aiming to reduce storage and clear accumulated substrates.
Sphingolipid Metabolism and Function
Sphingolipids including sphingomyelin represent an essential class of membrane
glycerophospholipids regulated by lysosomal catabolism:
- Biosynthesis involves serine palmitoyltransferase generating sphingoid long-chain bases,
followed by acylation to dihydroceramide then ceramide/sphingomyelin synthesis.
- Key sphingolipids act as second messengers/signaling molecules regulating proliferation,
apoptosis and autophagy through ceramide/sphingosine-1-phosphate rheostasis.
- Lysosomal ceramidase and acid sphingomyelinase hydrolyze complex sphingolipids,
ceramide and sphingomyelin for normal turnover.
- Sphingomyelin composes ~15% of brain myelin sheaths regulating neuronal integrity,
highlighting neurodegeneration consequences in NPD.
Defective ASM or redundancy pathways impairing substrate catabolism lead to storage,
compromising membrane organization and signaling networks driving disease
pathophysiology.
Clinical Features of NPD
Specific clinical features depend on neuron involvement severity:
NPD Type A
- Macrocrania, hepatosplenomegaly, vomiting, failure to thrive in infants.
- Rapidly progressive neurodegeneration, seizures, dysphagia and death by ages 2-3 without
transplantation.
NPD Type B
- Hepatosplenomegaly, vomiting initially, then varied outcomes.
- Late onset neurological signs - ataxia, dysarthria, seizures, dementia.
- Non-neurological signs - pulmonary disease, bone abnormalities.
Niemann-Pick C (NPC) Disorders
- Variable and multisystemic features based onNPC1/NPC2 gene defects.
- Hepatosplenomegaly, neurological findings, pulmonary/endocrine involvement.
Overall, brain macrophages/microglia accumulate sphingomyelin leading to
neurodegeneration severity differences dependent upon precise variants and residual enzyme
activity levels.
Genetics of NPD
All forms arise from defects in ASM (SMPD1), which encodes the lysosomal acid
sphingomyelinase enzyme:
- NPD Type A/B - Biallelic loss-of-function mutations in SMPD1 preventing sufficient ASM
levels.
- NPD Type A pseudo-deficiency - Homozygosity for splicing or missense variants
conferring residual activity.
Genotype-phenotype correlations link residual ASM amounts to severity, though variants
may not fully predict outcomes. Heterozygotes usually show no signs. Carrier testing of
relatives assesses risks.
Diagnosis
Typically based upon:
- Clinical suspicion from hepatosplenomegaly, neurological deterioration, bone
abnormalities.
- Enzyme activity assays on leukocytes/fibroblasts confirming <5% ASM activity.
- Genetic testing identifies biallelic SMPD1 variants establishing molecular diagnosis.
- MRI/CT reveals hepatic/spleen enlargement, brain atrophy in neurological cases.
- Sphingomyelin accumulation on tissue biopsy visualized histologically via filipin staining.
Early diagnosis guides screening family members and developing newborn screening
algorithms. Differential diagnosis excludes Gaucher’s disease.
Disease Management
No cure exists; care focuses reducing complications:
- Supportive care addresses pneumonias, poor nutrition in Type A.
- Seizure control utilizes anticonvulsants addressing neurological deterioration.
- Symptomatic care manages bone pain, movement disorders.
- Hematopoietic stem cell transplantation shows potential benefits for Type B.
- Substrate reduction therapies addressGSL storage defects in NPC variants.
- Enzyme replacement trials evaluate ASM supplementation or gene therapy concepts in
animal models.
Future perspectives
Progress targets neuroprotection through tailoring hematopoietic cell therapies, AAV-
delivered gene therapies replacing deficient ASM more broadly or addressing storage directly
through substrate inhibitors pending results from ongoing preclinical/clinical studies seeking
disease-modifying capabilities across NPD subtypes. Multi ‘omics may elucidate lysosomal
pathways amenable to modulation. Palliative symptom management still plays an essential
role in quality of life optimization.
Niemann-Pick disease (NPD) encompasses a group of autosomal recessive lipid storage
disorders arising from defective lysosomal acid sphingomyelinase (ASM) enzyme function,
impacting sphingomyelin metabolism and intracellular trafficking. Two major forms exist -
types A and B - distinguished by age of onset and visceral/neurological involvement severity.
Type A presents in infancy as a rapidly progressive, fatal neurological phenotype affecting
the lungs, liver and spleen. Type B has later childhood or adult onset with variable
progression.
Both arise from impaired sphingolipid catabolism building up in lysosomes. However,
mechanisms linking storage defects to tissue-specific manifestations remain unclear. While
hematopoietic stem cell transplantation shows potential benefits for Type B, no curative
treatments exist. This review surveys sphingomyelin biology, clinical features of NPD types,
the ASM gene/protein defective across subtypes, current management strategies and
emerging therapies targeting neurodegeneration outcomes through enzyme supplementation
or gene therapy aiming to reduce storage and clear accumulated substrates.
Sphingolipid Metabolism and Function
Sphingolipids including sphingomyelin represent an essential class of membrane
glycerophospholipids regulated by lysosomal catabolism:
- Biosynthesis involves serine palmitoyltransferase generating sphingoid long-chain bases,
followed by acylation to dihydroceramide then ceramide/sphingomyelin synthesis.
- Key sphingolipids act as second messengers/signaling molecules regulating proliferation,
apoptosis and autophagy through ceramide/sphingosine-1-phosphate rheostasis.
- Lysosomal ceramidase and acid sphingomyelinase hydrolyze complex sphingolipids,
ceramide and sphingomyelin for normal turnover.
- Sphingomyelin composes ~15% of brain myelin sheaths regulating neuronal integrity,
highlighting neurodegeneration consequences in NPD.
Defective ASM or redundancy pathways impairing substrate catabolism lead to storage,
compromising membrane organization and signaling networks driving disease
pathophysiology.
Clinical Features of NPD
Specific clinical features depend on neuron involvement severity:
NPD Type A
- Macrocrania, hepatosplenomegaly, vomiting, failure to thrive in infants.
- Rapidly progressive neurodegeneration, seizures, dysphagia and death by ages 2-3 without
transplantation.
NPD Type B
- Hepatosplenomegaly, vomiting initially, then varied outcomes.
- Late onset neurological signs - ataxia, dysarthria, seizures, dementia.
- Non-neurological signs - pulmonary disease, bone abnormalities.
Niemann-Pick C (NPC) Disorders
- Variable and multisystemic features based onNPC1/NPC2 gene defects.
- Hepatosplenomegaly, neurological findings, pulmonary/endocrine involvement.
Overall, brain macrophages/microglia accumulate sphingomyelin leading to
neurodegeneration severity differences dependent upon precise variants and residual enzyme
activity levels.
Genetics of NPD
All forms arise from defects in ASM (SMPD1), which encodes the lysosomal acid
sphingomyelinase enzyme:
- NPD Type A/B - Biallelic loss-of-function mutations in SMPD1 preventing sufficient ASM
levels.
- NPD Type A pseudo-deficiency - Homozygosity for splicing or missense variants
conferring residual activity.
Genotype-phenotype correlations link residual ASM amounts to severity, though variants
may not fully predict outcomes. Heterozygotes usually show no signs. Carrier testing of
relatives assesses risks.
Diagnosis
Typically based upon:
- Clinical suspicion from hepatosplenomegaly, neurological deterioration, bone
abnormalities.
- Enzyme activity assays on leukocytes/fibroblasts confirming <5% ASM activity.
- Genetic testing identifies biallelic SMPD1 variants establishing molecular diagnosis.
- MRI/CT reveals hepatic/spleen enlargement, brain atrophy in neurological cases.
- Sphingomyelin accumulation on tissue biopsy visualized histologically via filipin staining.
Early diagnosis guides screening family members and developing newborn screening
algorithms. Differential diagnosis excludes Gaucher’s disease.
Disease Management
No cure exists; care focuses reducing complications:
- Supportive care addresses pneumonias, poor nutrition in Type A.
- Seizure control utilizes anticonvulsants addressing neurological deterioration.
- Symptomatic care manages bone pain, movement disorders.
- Hematopoietic stem cell transplantation shows potential benefits for Type B.
- Substrate reduction therapies addressGSL storage defects in NPC variants.
- Enzyme replacement trials evaluate ASM supplementation or gene therapy concepts in
animal models.
Future perspectives
Progress targets neuroprotection through tailoring hematopoietic cell therapies, AAV-
delivered gene therapies replacing deficient ASM more broadly or addressing storage directly
through substrate inhibitors pending results from ongoing preclinical/clinical studies seeking
disease-modifying capabilities across NPD subtypes. Multi ‘omics may elucidate lysosomal
pathways amenable to modulation. Palliative symptom management still plays an essential
role in quality of life optimization.
Niemann-Pick disease (NPD) encompasses a group of autosomal recessive lipid storage
disorders arising from defective lysosomal acid sphingomyelinase (ASM) enzyme function,
impacting sphingomyelin metabolism and intracellular trafficking. Two major forms exist -
types A and B - distinguished by age of onset and visceral/neurological involvement severity.
Type A presents in infancy as a rapidly progressive, fatal neurological phenotype affecting
the lungs, liver and spleen. Type B has later childhood or adult onset with variable
progression.
Both arise from impaired sphingolipid catabolism building up in lysosomes. However,
mechanisms linking storage defects to tissue-specific manifestations remain unclear. While
hematopoietic stem cell transplantation shows potential benefits for Type B, no curative
treatments exist. This review surveys sphingomyelin biology, clinical features of NPD types,
the ASM gene/protein defective across subtypes, current management strategies and
emerging therapies targeting neurodegeneration outcomes through enzyme supplementation
or gene therapy aiming to reduce storage and clear accumulated substrates.
Sphingolipid Metabolism and Function
Sphingolipids including sphingomyelin represent an essential class of membrane
glycerophospholipids regulated by lysosomal catabolism:
- Biosynthesis involves serine palmitoyltransferase generating sphingoid long-chain bases,
followed by acylation to dihydroceramide then ceramide/sphingomyelin synthesis.
- Key sphingolipids act as second messengers/signaling molecules regulating proliferation,
apoptosis and autophagy through ceramide/sphingosine-1-phosphate rheostasis.
- Lysosomal ceramidase and acid sphingomyelinase hydrolyze complex sphingolipids,
ceramide and sphingomyelin for normal turnover.
- Sphingomyelin composes ~15% of brain myelin sheaths regulating neuronal integrity,
highlighting neurodegeneration consequences in NPD.
Defective ASM or redundancy pathways impairing substrate catabolism lead to storage,
compromising membrane organization and signaling networks driving disease
pathophysiology.
Clinical Features of NPD
Specific clinical features depend on neuron involvement severity:
NPD Type A
- Macrocrania, hepatosplenomegaly, vomiting, failure to thrive in infants.
- Rapidly progressive neurodegeneration, seizures, dysphagia and death by ages 2-3 without
transplantation.
NPD Type B
- Hepatosplenomegaly, vomiting initially, then varied outcomes.
- Late onset neurological signs - ataxia, dysarthria, seizures, dementia.
- Non-neurological signs - pulmonary disease, bone abnormalities.
Niemann-Pick C (NPC) Disorders
- Variable and multisystemic features based onNPC1/NPC2 gene defects.
- Hepatosplenomegaly, neurological findings, pulmonary/endocrine involvement.
Overall, brain macrophages/microglia accumulate sphingomyelin leading to
neurodegeneration severity differences dependent upon precise variants and residual enzyme
activity levels.
Genetics of NPD
All forms arise from defects in ASM (SMPD1), which encodes the lysosomal acid
sphingomyelinase enzyme:
- NPD Type A/B - Biallelic loss-of-function mutations in SMPD1 preventing sufficient ASM
levels.
- NPD Type A pseudo-deficiency - Homozygosity for splicing or missense variants
conferring residual activity.
Genotype-phenotype correlations link residual ASM amounts to severity, though variants
may not fully predict outcomes. Heterozygotes usually show no signs. Carrier testing of
relatives assesses risks.
Diagnosis
Typically based upon:
- Clinical suspicion from hepatosplenomegaly, neurological deterioration, bone
abnormalities.
- Enzyme activity assays on leukocytes/fibroblasts confirming <5% ASM activity.
- Genetic testing identifies biallelic SMPD1 variants establishing molecular diagnosis.
- MRI/CT reveals hepatic/spleen enlargement, brain atrophy in neurological cases.
- Sphingomyelin accumulation on tissue biopsy visualized histologically via filipin staining.
Early diagnosis guides screening family members and developing newborn screening
algorithms. Differential diagnosis excludes Gaucher’s disease.
Disease Management
No cure exists; care focuses reducing complications:
- Supportive care addresses pneumonias, poor nutrition in Type A.
- Seizure control utilizes anticonvulsants addressing neurological deterioration.
- Symptomatic care manages bone pain, movement disorders.
- Hematopoietic stem cell transplantation shows potential benefits for Type B.
- Substrate reduction therapies addressGSL storage defects in NPC variants.
- Enzyme replacement trials evaluate ASM supplementation or gene therapy concepts in
animal models.
Future perspectives
Progress targets neuroprotection through tailoring hematopoietic cell therapies, AAV-
delivered gene therapies replacing deficient ASM more broadly or addressing storage directly
through substrate inhibitors pending results from ongoing preclinical/clinical studies seeking
disease-modifying capabilities across NPD subtypes. Multi ‘omics may elucidate lysosomal
pathways amenable to modulation. Palliative symptom management still plays an essential
role in quality of life optimization.
Niemann-Pick disease (NPD) encompasses a group of autosomal recessive lipid storage
disorders arising from defective lysosomal acid sphingomyelinase (ASM) enzyme function,
impacting sphingomyelin metabolism and intracellular trafficking. Two major forms exist -
types A and B - distinguished by age of onset and visceral/neurological involvement severity.
Type A presents in infancy as a rapidly progressive, fatal neurological phenotype affecting
the lungs, liver and spleen. Type B has later childhood or adult onset with variable
progression.
Both arise from impaired sphingolipid catabolism building up in lysosomes. However,
mechanisms linking storage defects to tissue-specific manifestations remain unclear. While
hematopoietic stem cell transplantation shows potential benefits for Type B, no curative
treatments exist. This review surveys sphingomyelin biology, clinical features of NPD types,
the ASM gene/protein defective across subtypes, current management strategies and
emerging therapies targeting neurodegeneration outcomes through enzyme supplementation
or gene therapy aiming to reduce storage and clear accumulated substrates.
Sphingolipid Metabolism and Function
Sphingolipids including sphingomyelin represent an essential class of membrane
glycerophospholipids regulated by lysosomal catabolism:
- Biosynthesis involves serine palmitoyltransferase generating sphingoid long-chain bases,
followed by acylation to dihydroceramide then ceramide/sphingomyelin synthesis.
- Key sphingolipids act as second messengers/signaling molecules regulating proliferation,
apoptosis and autophagy through ceramide/sphingosine-1-phosphate rheostasis.
- Lysosomal ceramidase and acid sphingomyelinase hydrolyze complex sphingolipids,
ceramide and sphingomyelin for normal turnover.
- Sphingomyelin composes ~15% of brain myelin sheaths regulating neuronal integrity,
highlighting neurodegeneration consequences in NPD.
Defective ASM or redundancy pathways impairing substrate catabolism lead to storage,
compromising membrane organization and signaling networks driving disease
pathophysiology.
Clinical Features of NPD
Specific clinical features depend on neuron involvement severity:
NPD Type A
- Macrocrania, hepatosplenomegaly, vomiting, failure to thrive in infants.
- Rapidly progressive neurodegeneration, seizures, dysphagia and death by ages 2-3 without
transplantation.
NPD Type B
- Hepatosplenomegaly, vomiting initially, then varied outcomes.
- Late onset neurological signs - ataxia, dysarthria, seizures, dementia.
- Non-neurological signs - pulmonary disease, bone abnormalities.
Niemann-Pick C (NPC) Disorders
- Variable and multisystemic features based onNPC1/NPC2 gene defects.
- Hepatosplenomegaly, neurological findings, pulmonary/endocrine involvement.
Overall, brain macrophages/microglia accumulate sphingomyelin leading to
neurodegeneration severity differences dependent upon precise variants and residual enzyme
activity levels.
Genetics of NPD
All forms arise from defects in ASM (SMPD1), which encodes the lysosomal acid
sphingomyelinase enzyme:
- NPD Type A/B - Biallelic loss-of-function mutations in SMPD1 preventing sufficient ASM
levels.
- NPD Type A pseudo-deficiency - Homozygosity for splicing or missense variants
conferring residual activity.
Genotype-phenotype correlations link residual ASM amounts to severity, though variants
may not fully predict outcomes. Heterozygotes usually show no signs. Carrier testing of
relatives assesses risks.
Diagnosis
Typically based upon:
- Clinical suspicion from hepatosplenomegaly, neurological deterioration, bone
abnormalities.
- Enzyme activity assays on leukocytes/fibroblasts confirming <5% ASM activity.
- Genetic testing identifies biallelic SMPD1 variants establishing molecular diagnosis.
- MRI/CT reveals hepatic/spleen enlargement, brain atrophy in neurological cases.
- Sphingomyelin accumulation on tissue biopsy visualized histologically via filipin staining.
Early diagnosis guides screening family members and developing newborn screening
algorithms. Differential diagnosis excludes Gaucher’s disease.
Disease Management
No cure exists; care focuses reducing complications:
- Supportive care addresses pneumonias, poor nutrition in Type A.
- Seizure control utilizes anticonvulsants addressing neurological deterioration.
- Symptomatic care manages bone pain, movement disorders.
- Hematopoietic stem cell transplantation shows potential benefits for Type B.
- Substrate reduction therapies addressGSL storage defects in NPC variants.
- Enzyme replacement trials evaluate ASM supplementation or gene therapy concepts in
animal models.
Future perspectives
Progress targets neuroprotection through tailoring hematopoietic cell therapies, AAV-
delivered gene therapies replacing deficient ASM more broadly or addressing storage directly
through substrate inhibitors pending results from ongoing preclinical/clinical studies seeking
disease-modifying capabilities across NPD subtypes. Multi ‘omics may elucidate lysosomal
pathways amenable to modulation. Palliative symptom management still plays an essential
role in quality of life optimization.
Niemann-Pick disease (NPD) encompasses a group of autosomal recessive lipid storage
disorders arising from defective lysosomal acid sphingomyelinase (ASM) enzyme function,
impacting sphingomyelin metabolism and intracellular trafficking. Two major forms exist -
types A and B - distinguished by age of onset and visceral/neurological involvement severity.
Type A presents in infancy as a rapidly progressive, fatal neurological phenotype affecting
the lungs, liver and spleen. Type B has later childhood or adult onset with variable
progression.
Both arise from impaired sphingolipid catabolism building up in lysosomes. However,
mechanisms linking storage defects to tissue-specific manifestations remain unclear. While
hematopoietic stem cell transplantation shows potential benefits for Type B, no curative
treatments exist. This review surveys sphingomyelin biology, clinical features of NPD types,
the ASM gene/protein defective across subtypes, current management strategies and
emerging therapies targeting neurodegeneration outcomes through enzyme supplementation
or gene therapy aiming to reduce storage and clear accumulated substrates.
Sphingolipid Metabolism and Function
Sphingolipids including sphingomyelin represent an essential class of membrane
glycerophospholipids regulated by lysosomal catabolism:
- Biosynthesis involves serine palmitoyltransferase generating sphingoid long-chain bases,
followed by acylation to dihydroceramide then ceramide/sphingomyelin synthesis.
- Key sphingolipids act as second messengers/signaling molecules regulating proliferation,
apoptosis and autophagy through ceramide/sphingosine-1-phosphate rheostasis.
- Lysosomal ceramidase and acid sphingomyelinase hydrolyze complex sphingolipids,
ceramide and sphingomyelin for normal turnover.
- Sphingomyelin composes ~15% of brain myelin sheaths regulating neuronal integrity,
highlighting neurodegeneration consequences in NPD.
Defective ASM or redundancy pathways impairing substrate catabolism lead to storage,
compromising membrane organization and signaling networks driving disease
pathophysiology.
Clinical Features of NPD
Specific clinical features depend on neuron involvement severity:
NPD Type A
- Macrocrania, hepatosplenomegaly, vomiting, failure to thrive in infants.
- Rapidly progressive neurodegeneration, seizures, dysphagia and death by ages 2-3 without
transplantation.
NPD Type B
- Hepatosplenomegaly, vomiting initially, then varied outcomes.
- Late onset neurological signs - ataxia, dysarthria, seizures, dementia.
- Non-neurological signs - pulmonary disease, bone abnormalities.
Niemann-Pick C (NPC) Disorders
- Variable and multisystemic features based onNPC1/NPC2 gene defects.
- Hepatosplenomegaly, neurological findings, pulmonary/endocrine involvement.
Overall, brain macrophages/microglia accumulate sphingomyelin leading to
neurodegeneration severity differences dependent upon precise variants and residual enzyme
activity levels.
Genetics of NPD
All forms arise from defects in ASM (SMPD1), which encodes the lysosomal acid
sphingomyelinase enzyme:
- NPD Type A/B - Biallelic loss-of-function mutations in SMPD1 preventing sufficient ASM
levels.
- NPD Type A pseudo-deficiency - Homozygosity for splicing or missense variants
conferring residual activity.
Genotype-phenotype correlations link residual ASM amounts to severity, though variants
may not fully predict outcomes. Heterozygotes usually show no signs. Carrier testing of
relatives assesses risks.
Diagnosis
Typically based upon:
- Clinical suspicion from hepatosplenomegaly, neurological deterioration, bone
abnormalities.
- Enzyme activity assays on leukocytes/fibroblasts confirming <5% ASM activity.
- Genetic testing identifies biallelic SMPD1 variants establishing molecular diagnosis.
- MRI/CT reveals hepatic/spleen enlargement, brain atrophy in neurological cases.
- Sphingomyelin accumulation on tissue biopsy visualized histologically via filipin staining.
Early diagnosis guides screening family members and developing newborn screening
algorithms. Differential diagnosis excludes Gaucher’s disease.
Disease Management
No cure exists; care focuses reducing complications:
- Supportive care addresses pneumonias, poor nutrition in Type A.
- Seizure control utilizes anticonvulsants addressing neurological deterioration.
- Symptomatic care manages bone pain, movement disorders.
- Hematopoietic stem cell transplantation shows potential benefits for Type B.
- Substrate reduction therapies addressGSL storage defects in NPC variants.
- Enzyme replacement trials evaluate ASM supplementation or gene therapy concepts in
animal models.
Future perspectives
Progress targets neuroprotection through tailoring hematopoietic cell therapies, AAV-
delivered gene therapies replacing deficient ASM more broadly or addressing storage directly
through substrate inhibitors pending results from ongoing preclinical/clinical studies seeking
disease-modifying capabilities across NPD subtypes. Multi ‘omics may elucidate lysosomal
pathways amenable to modulation. Palliative symptom management still plays an essential
role in quality of life optimization.
Niemann-Pick disease (NPD) encompasses a group of autosomal recessive lipid storage
disorders arising from defective lysosomal acid sphingomyelinase (ASM) enzyme function,
impacting sphingomyelin metabolism and intracellular trafficking. Two major forms exist -
types A and B - distinguished by age of onset and visceral/neurological involvement severity.
Type A presents in infancy as a rapidly progressive, fatal neurological phenotype affecting
the lungs, liver and spleen. Type B has later childhood or adult onset with variable
progression.
Both arise from impaired sphingolipid catabolism building up in lysosomes. However,
mechanisms linking storage defects to tissue-specific manifestations remain unclear. While
hematopoietic stem cell transplantation shows potential benefits for Type B, no curative
treatments exist. This review surveys sphingomyelin biology, clinical features of NPD types,
the ASM gene/protein defective across subtypes, current management strategies and
emerging therapies targeting neurodegeneration outcomes through enzyme supplementation
or gene therapy aiming to reduce storage and clear accumulated substrates.
Sphingolipid Metabolism and Function
Sphingolipids including sphingomyelin represent an essential class of membrane
glycerophospholipids regulated by lysosomal catabolism:
- Biosynthesis involves serine palmitoyltransferase generating sphingoid long-chain bases,
followed by acylation to dihydroceramide then ceramide/sphingomyelin synthesis.
- Key sphingolipids act as second messengers/signaling molecules regulating proliferation,
apoptosis and autophagy through ceramide/sphingosine-1-phosphate rheostasis.
- Lysosomal ceramidase and acid sphingomyelinase hydrolyze complex sphingolipids,
ceramide and sphingomyelin for normal turnover.
- Sphingomyelin composes ~15% of brain myelin sheaths regulating neuronal integrity,
highlighting neurodegeneration consequences in NPD.
Defective ASM or redundancy pathways impairing substrate catabolism lead to storage,
compromising membrane organization and signaling networks driving disease
pathophysiology.
Clinical Features of NPD
Specific clinical features depend on neuron involvement severity:
NPD Type A
- Macrocrania, hepatosplenomegaly, vomiting, failure to thrive in infants.
- Rapidly progressive neurodegeneration, seizures, dysphagia and death by ages 2-3 without
transplantation.
NPD Type B
- Hepatosplenomegaly, vomiting initially, then varied outcomes.
- Late onset neurological signs - ataxia, dysarthria, seizures, dementia.
- Non-neurological signs - pulmonary disease, bone abnormalities.
Niemann-Pick C (NPC) Disorders
- Variable and multisystemic features based onNPC1/NPC2 gene defects.
- Hepatosplenomegaly, neurological findings, pulmonary/endocrine involvement.
Overall, brain macrophages/microglia accumulate sphingomyelin leading to
neurodegeneration severity differences dependent upon precise variants and residual enzyme
activity levels.
Genetics of NPD
All forms arise from defects in ASM (SMPD1), which encodes the lysosomal acid
sphingomyelinase enzyme:
- NPD Type A/B - Biallelic loss-of-function mutations in SMPD1 preventing sufficient ASM
levels.
- NPD Type A pseudo-deficiency - Homozygosity for splicing or missense variants
conferring residual activity.
Genotype-phenotype correlations link residual ASM amounts to severity, though variants
may not fully predict outcomes. Heterozygotes usually show no signs. Carrier testing of
relatives assesses risks.
Diagnosis
Typically based upon:
- Clinical suspicion from hepatosplenomegaly, neurological deterioration, bone
abnormalities.
- Enzyme activity assays on leukocytes/fibroblasts confirming <5% ASM activity.
- Genetic testing identifies biallelic SMPD1 variants establishing molecular diagnosis.
- MRI/CT reveals hepatic/spleen enlargement, brain atrophy in neurological cases.
- Sphingomyelin accumulation on tissue biopsy visualized histologically via filipin staining.
Early diagnosis guides screening family members and developing newborn screening
algorithms. Differential diagnosis excludes Gaucher’s disease.
Disease Management
No cure exists; care focuses reducing complications:
- Supportive care addresses pneumonias, poor nutrition in Type A.
- Seizure control utilizes anticonvulsants addressing neurological deterioration.
- Symptomatic care manages bone pain, movement disorders.
- Hematopoietic stem cell transplantation shows potential benefits for Type B.
- Substrate reduction therapies addressGSL storage defects in NPC variants.
- Enzyme replacement trials evaluate ASM supplementation or gene therapy concepts in
animal models.
Future perspectives
Progress targets neuroprotection through tailoring hematopoietic cell therapies, AAV-
delivered gene therapies replacing deficient ASM more broadly or addressing storage directly
through substrate inhibitors pending results from ongoing preclinical/clinical studies seeking
disease-modifying capabilities across NPD subtypes. Multi ‘omics may elucidate lysosomal
pathways amenable to modulation. Palliative symptom management still plays an essential
role in quality of life optimization.
Niemann-Pick disease (NPD) encompasses a group of autosomal recessive lipid storage
disorders arising from defective lysosomal acid sphingomyelinase (ASM) enzyme function,
impacting sphingomyelin metabolism and intracellular trafficking. Two major forms exist -
types A and B - distinguished by age of onset and visceral/neurological involvement severity.
Type A presents in infancy as a rapidly progressive, fatal neurological phenotype affecting
the lungs, liver and spleen. Type B has later childhood or adult onset with variable
progression.
Both arise from impaired sphingolipid catabolism building up in lysosomes. However,
mechanisms linking storage defects to tissue-specific manifestations remain unclear. While
hematopoietic stem cell transplantation shows potential benefits for Type B, no curative
treatments exist. This review surveys sphingomyelin biology, clinical features of NPD types,
the ASM gene/protein defective across subtypes, current management strategies and
emerging therapies targeting neurodegeneration outcomes through enzyme supplementation
or gene therapy aiming to reduce storage and clear accumulated substrates.
Sphingolipid Metabolism and Function
Sphingolipids including sphingomyelin represent an essential class of membrane
glycerophospholipids regulated by lysosomal catabolism:
- Biosynthesis involves serine palmitoyltransferase generating sphingoid long-chain bases,
followed by acylation to dihydroceramide then ceramide/sphingomyelin synthesis.
- Key sphingolipids act as second messengers/signaling molecules regulating proliferation,
apoptosis and autophagy through ceramide/sphingosine-1-phosphate rheostasis.
- Lysosomal ceramidase and acid sphingomyelinase hydrolyze complex sphingolipids,
ceramide and sphingomyelin for normal turnover.
- Sphingomyelin composes ~15% of brain myelin sheaths regulating neuronal integrity,
highlighting neurodegeneration consequences in NPD.
Defective ASM or redundancy pathways impairing substrate catabolism lead to storage,
compromising membrane organization and signaling networks driving disease
pathophysiology.
Clinical Features of NPD
Specific clinical features depend on neuron involvement severity:
NPD Type A
- Macrocrania, hepatosplenomegaly, vomiting, failure to thrive in infants.
- Rapidly progressive neurodegeneration, seizures, dysphagia and death by ages 2-3 without
transplantation.
NPD Type B
- Hepatosplenomegaly, vomiting initially, then varied outcomes.
- Late onset neurological signs - ataxia, dysarthria, seizures, dementia.
- Non-neurological signs - pulmonary disease, bone abnormalities.
Niemann-Pick C (NPC) Disorders
- Variable and multisystemic features based onNPC1/NPC2 gene defects.
- Hepatosplenomegaly, neurological findings, pulmonary/endocrine involvement.
Overall, brain macrophages/microglia accumulate sphingomyelin leading to
neurodegeneration severity differences dependent upon precise variants and residual enzyme
activity levels.
Genetics of NPD
All forms arise from defects in ASM (SMPD1), which encodes the lysosomal acid
sphingomyelinase enzyme:
- NPD Type A/B - Biallelic loss-of-function mutations in SMPD1 preventing sufficient ASM
levels.
- NPD Type A pseudo-deficiency - Homozygosity for splicing or missense variants
conferring residual activity.
Genotype-phenotype correlations link residual ASM amounts to severity, though variants
may not fully predict outcomes. Heterozygotes usually show no signs. Carrier testing of
relatives assesses risks.
Diagnosis
Typically based upon:
- Clinical suspicion from hepatosplenomegaly, neurological deterioration, bone
abnormalities.
- Enzyme activity assays on leukocytes/fibroblasts confirming <5% ASM activity.
- Genetic testing identifies biallelic SMPD1 variants establishing molecular diagnosis.
- MRI/CT reveals hepatic/spleen enlargement, brain atrophy in neurological cases.
- Sphingomyelin accumulation on tissue biopsy visualized histologically via filipin staining.
Early diagnosis guides screening family members and developing newborn screening
algorithms. Differential diagnosis excludes Gaucher’s disease.
Disease Management
No cure exists; care focuses reducing complications:
- Supportive care addresses pneumonias, poor nutrition in Type A.
- Seizure control utilizes anticonvulsants addressing neurological deterioration.
- Symptomatic care manages bone pain, movement disorders.
- Hematopoietic stem cell transplantation shows potential benefits for Type B.
- Substrate reduction therapies addressGSL storage defects in NPC variants.
- Enzyme replacement trials evaluate ASM supplementation or gene therapy concepts in
animal models.
Future perspectives
Progress targets neuroprotection through tailoring hematopoietic cell therapies, AAV-
delivered gene therapies replacing deficient ASM more broadly or addressing storage directly
through substrate inhibitors pending results from ongoing preclinical/clinical studies seeking
disease-modifying capabilities across NPD subtypes. Multi ‘omics may elucidate lysosomal
pathways amenable to modulation. Palliative symptom management still plays an essential
role in quality of life optimization.
Niemann-Pick disease (NPD) encompasses a group of autosomal recessive lipid storage
disorders arising from defective lysosomal acid sphingomyelinase (ASM) enzyme function,
impacting sphingomyelin metabolism and intracellular trafficking. Two major forms exist -
types A and B - distinguished by age of onset and visceral/neurological involvement severity.
Type A presents in infancy as a rapidly progressive, fatal neurological phenotype affecting
the lungs, liver and spleen. Type B has later childhood or adult onset with variable
progression.
Both arise from impaired sphingolipid catabolism building up in lysosomes. However,
mechanisms linking storage defects to tissue-specific manifestations remain unclear. While
hematopoietic stem cell transplantation shows potential benefits for Type B, no curative
treatments exist. This review surveys sphingomyelin biology, clinical features of NPD types,
the ASM gene/protein defective across subtypes, current management strategies and
emerging therapies targeting neurodegeneration outcomes through enzyme supplementation
or gene therapy aiming to reduce storage and clear accumulated substrates.
Sphingolipid Metabolism and Function
Sphingolipids including sphingomyelin represent an essential class of membrane
glycerophospholipids regulated by lysosomal catabolism:
- Biosynthesis involves serine palmitoyltransferase generating sphingoid long-chain bases,
followed by acylation to dihydroceramide then ceramide/sphingomyelin synthesis.
- Key sphingolipids act as second messengers/signaling molecules regulating proliferation,
apoptosis and autophagy through ceramide/sphingosine-1-phosphate rheostasis.
- Lysosomal ceramidase and acid sphingomyelinase hydrolyze complex sphingolipids,
ceramide and sphingomyelin for normal turnover.
- Sphingomyelin composes ~15% of brain myelin sheaths regulating neuronal integrity,
highlighting neurodegeneration consequences in NPD.
Defective ASM or redundancy pathways impairing substrate catabolism lead to storage,
compromising membrane organization and signaling networks driving disease
pathophysiology.
Clinical Features of NPD
Specific clinical features depend on neuron involvement severity:
NPD Type A
- Macrocrania, hepatosplenomegaly, vomiting, failure to thrive in infants.
- Rapidly progressive neurodegeneration, seizures, dysphagia and death by ages 2-3 without
transplantation.
NPD Type B
- Hepatosplenomegaly, vomiting initially, then varied outcomes.
- Late onset neurological signs - ataxia, dysarthria, seizures, dementia.
- Non-neurological signs - pulmonary disease, bone abnormalities.
Niemann-Pick C (NPC) Disorders
- Variable and multisystemic features based onNPC1/NPC2 gene defects.
- Hepatosplenomegaly, neurological findings, pulmonary/endocrine involvement.
Overall, brain macrophages/microglia accumulate sphingomyelin leading to
neurodegeneration severity differences dependent upon precise variants and residual enzyme
activity levels.
Genetics of NPD
All forms arise from defects in ASM (SMPD1), which encodes the lysosomal acid
sphingomyelinase enzyme:
- NPD Type A/B - Biallelic loss-of-function mutations in SMPD1 preventing sufficient ASM
levels.
- NPD Type A pseudo-deficiency - Homozygosity for splicing or missense variants
conferring residual activity.
Genotype-phenotype correlations link residual ASM amounts to severity, though variants
may not fully predict outcomes. Heterozygotes usually show no signs. Carrier testing of
relatives assesses risks.
Diagnosis
Typically based upon:
- Clinical suspicion from hepatosplenomegaly, neurological deterioration, bone
abnormalities.
- Enzyme activity assays on leukocytes/fibroblasts confirming <5% ASM activity.
- Genetic testing identifies biallelic SMPD1 variants establishing molecular diagnosis.
- MRI/CT reveals hepatic/spleen enlargement, brain atrophy in neurological cases.
- Sphingomyelin accumulation on tissue biopsy visualized histologically via filipin staining.
Early diagnosis guides screening family members and developing newborn screening
algorithms. Differential diagnosis excludes Gaucher’s disease.
Disease Management
No cure exists; care focuses reducing complications:
- Supportive care addresses pneumonias, poor nutrition in Type A.
- Seizure control utilizes anticonvulsants addressing neurological deterioration.
- Symptomatic care manages bone pain, movement disorders.
- Hematopoietic stem cell transplantation shows potential benefits for Type B.
- Substrate reduction therapies addressGSL storage defects in NPC variants.
- Enzyme replacement trials evaluate ASM supplementation or gene therapy concepts in
animal models.
Future perspectives
Progress targets neuroprotection through tailoring hematopoietic cell therapies, AAV-
delivered gene therapies replacing deficient ASM more broadly or addressing storage directly
through substrate inhibitors pending results from ongoing preclinical/clinical studies seeking
disease-modifying capabilities across NPD subtypes. Multi ‘omics may elucidate lysosomal
pathways amenable to modulation. Palliative symptom management still plays an essential
role in quality of life optimization.
Niemann-Pick disease (NPD) encompasses a group of autosomal recessive lipid storage
disorders arising from defective lysosomal acid sphingomyelinase (ASM) enzyme function,
impacting sphingomyelin metabolism and intracellular trafficking. Two major forms exist -
types A and B - distinguished by age of onset and visceral/neurological involvement severity.
Type A presents in infancy as a rapidly progressive, fatal neurological phenotype affecting
the lungs, liver and spleen. Type B has later childhood or adult onset with variable
progression.
Both arise from impaired sphingolipid catabolism building up in lysosomes. However,
mechanisms linking storage defects to tissue-specific manifestations remain unclear. While
hematopoietic stem cell transplantation shows potential benefits for Type B, no curative
treatments exist. This review surveys sphingomyelin biology, clinical features of NPD types,
the ASM gene/protein defective across subtypes, current management strategies and
emerging therapies targeting neurodegeneration outcomes through enzyme supplementation
or gene therapy aiming to reduce storage and clear accumulated substrates.
Sphingolipid Metabolism and Function
Sphingolipids including sphingomyelin represent an essential class of membrane
glycerophospholipids regulated by lysosomal catabolism:
- Biosynthesis involves serine palmitoyltransferase generating sphingoid long-chain bases,
followed by acylation to dihydroceramide then ceramide/sphingomyelin synthesis.
- Key sphingolipids act as second messengers/signaling molecules regulating proliferation,
apoptosis and autophagy through ceramide/sphingosine-1-phosphate rheostasis.
- Lysosomal ceramidase and acid sphingomyelinase hydrolyze complex sphingolipids,
ceramide and sphingomyelin for normal turnover.
- Sphingomyelin composes ~15% of brain myelin sheaths regulating neuronal integrity,
highlighting neurodegeneration consequences in NPD.
Defective ASM or redundancy pathways impairing substrate catabolism lead to storage,
compromising membrane organization and signaling networks driving disease
pathophysiology.
Clinical Features of NPD
Specific clinical features depend on neuron involvement severity:
NPD Type A
- Macrocrania, hepatosplenomegaly, vomiting, failure to thrive in infants.
- Rapidly progressive neurodegeneration, seizures, dysphagia and death by ages 2-3 without
transplantation.
NPD Type B
- Hepatosplenomegaly, vomiting initially, then varied outcomes.
- Late onset neurological signs - ataxia, dysarthria, seizures, dementia.
- Non-neurological signs - pulmonary disease, bone abnormalities.
Niemann-Pick C (NPC) Disorders
- Variable and multisystemic features based onNPC1/NPC2 gene defects.
- Hepatosplenomegaly, neurological findings, pulmonary/endocrine involvement.
Overall, brain macrophages/microglia accumulate sphingomyelin leading to
neurodegeneration severity differences dependent upon precise variants and residual enzyme
activity levels.
Genetics of NPD
All forms arise from defects in ASM (SMPD1), which encodes the lysosomal acid
sphingomyelinase enzyme:
- NPD Type A/B - Biallelic loss-of-function mutations in SMPD1 preventing sufficient ASM
levels.
- NPD Type A pseudo-deficiency - Homozygosity for splicing or missense variants
conferring residual activity.
Genotype-phenotype correlations link residual ASM amounts to severity, though variants
may not fully predict outcomes. Heterozygotes usually show no signs. Carrier testing of
relatives assesses risks.
Diagnosis
Typically based upon:
- Clinical suspicion from hepatosplenomegaly, neurological deterioration, bone
abnormalities.
- Enzyme activity assays on leukocytes/fibroblasts confirming <5% ASM activity.
- Genetic testing identifies biallelic SMPD1 variants establishing molecular diagnosis.
- MRI/CT reveals hepatic/spleen enlargement, brain atrophy in neurological cases.
- Sphingomyelin accumulation on tissue biopsy visualized histologically via filipin staining.
Early diagnosis guides screening family members and developing newborn screening
algorithms. Differential diagnosis excludes Gaucher’s disease.
Disease Management
No cure exists; care focuses reducing complications:
- Supportive care addresses pneumonias, poor nutrition in Type A.
- Seizure control utilizes anticonvulsants addressing neurological deterioration.
- Symptomatic care manages bone pain, movement disorders.
- Hematopoietic stem cell transplantation shows potential benefits for Type B.
- Substrate reduction therapies addressGSL storage defects in NPC variants.
- Enzyme replacement trials evaluate ASM supplementation or gene therapy concepts in
animal models.
Future perspectives
Progress targets neuroprotection through tailoring hematopoietic cell therapies, AAV-
delivered gene therapies replacing deficient ASM more broadly or addressing storage directly
through substrate inhibitors pending results from ongoing preclinical/clinical studies seeking
disease-modifying capabilities across NPD subtypes. Multi ‘omics may elucidate lysosomal
pathways amenable to modulation. Palliative symptom management still plays an essential
role in quality of life optimization.
Niemann-Pick disease (NPD) encompasses a group of autosomal recessive lipid storage
disorders arising from defective lysosomal acid sphingomyelinase (ASM) enzyme function,
impacting sphingomyelin metabolism and intracellular trafficking. Two major forms exist -
types A and B - distinguished by age of onset and visceral/neurological involvement severity.
Type A presents in infancy as a rapidly progressive, fatal neurological phenotype affecting
the lungs, liver and spleen. Type B has later childhood or adult onset with variable
progression.
Both arise from impaired sphingolipid catabolism building up in lysosomes. However,
mechanisms linking storage defects to tissue-specific manifestations remain unclear. While
hematopoietic stem cell transplantation shows potential benefits for Type B, no curative
treatments exist. This review surveys sphingomyelin biology, clinical features of NPD types,
the ASM gene/protein defective across subtypes, current management strategies and
emerging therapies targeting neurodegeneration outcomes through enzyme supplementation
or gene therapy aiming to reduce storage and clear accumulated substrates.
Sphingolipid Metabolism and Function
Sphingolipids including sphingomyelin represent an essential class of membrane
glycerophospholipids regulated by lysosomal catabolism:
- Biosynthesis involves serine palmitoyltransferase generating sphingoid long-chain bases,
followed by acylation to dihydroceramide then ceramide/sphingomyelin synthesis.
- Key sphingolipids act as second messengers/signaling molecules regulating proliferation,
apoptosis and autophagy through ceramide/sphingosine-1-phosphate rheostasis.
- Lysosomal ceramidase and acid sphingomyelinase hydrolyze complex sphingolipids,
ceramide and sphingomyelin for normal turnover.
- Sphingomyelin composes ~15% of brain myelin sheaths regulating neuronal integrity,
highlighting neurodegeneration consequences in NPD.
Defective ASM or redundancy pathways impairing substrate catabolism lead to storage,
compromising membrane organization and signaling networks driving disease
pathophysiology.
Clinical Features of NPD
Specific clinical features depend on neuron involvement severity:
NPD Type A
- Macrocrania, hepatosplenomegaly, vomiting, failure to thrive in infants.
- Rapidly progressive neurodegeneration, seizures, dysphagia and death by ages 2-3 without
transplantation.
NPD Type B
- Hepatosplenomegaly, vomiting initially, then varied outcomes.
- Late onset neurological signs - ataxia, dysarthria, seizures, dementia.
- Non-neurological signs - pulmonary disease, bone abnormalities.
Niemann-Pick C (NPC) Disorders
- Variable and multisystemic features based onNPC1/NPC2 gene defects.
- Hepatosplenomegaly, neurological findings, pulmonary/endocrine involvement.
Overall, brain macrophages/microglia accumulate sphingomyelin leading to
neurodegeneration severity differences dependent upon precise variants and residual enzyme
activity levels.
Genetics of NPD
All forms arise from defects in ASM (SMPD1), which encodes the lysosomal acid
sphingomyelinase enzyme:
- NPD Type A/B - Biallelic loss-of-function mutations in SMPD1 preventing sufficient ASM
levels.
- NPD Type A pseudo-deficiency - Homozygosity for splicing or missense variants
conferring residual activity.
Genotype-phenotype correlations link residual ASM amounts to severity, though variants
may not fully predict outcomes. Heterozygotes usually show no signs. Carrier testing of
relatives assesses risks.
Diagnosis
Typically based upon:
- Clinical suspicion from hepatosplenomegaly, neurological deterioration, bone
abnormalities.
- Enzyme activity assays on leukocytes/fibroblasts confirming <5% ASM activity.
- Genetic testing identifies biallelic SMPD1 variants establishing molecular diagnosis.
- MRI/CT reveals hepatic/spleen enlargement, brain atrophy in neurological cases.
- Sphingomyelin accumulation on tissue biopsy visualized histologically via filipin staining.
Early diagnosis guides screening family members and developing newborn screening
algorithms. Differential diagnosis excludes Gaucher’s disease.
Disease Management
No cure exists; care focuses reducing complications:
- Supportive care addresses pneumonias, poor nutrition in Type A.
- Seizure control utilizes anticonvulsants addressing neurological deterioration.
- Symptomatic care manages bone pain, movement disorders.
- Hematopoietic stem cell transplantation shows potential benefits for Type B.
- Substrate reduction therapies addressGSL storage defects in NPC variants.
- Enzyme replacement trials evaluate ASM supplementation or gene therapy concepts in
animal models.
Future perspectives
Progress targets neuroprotection through tailoring hematopoietic cell therapies, AAV-
delivered gene therapies replacing deficient ASM more broadly or addressing storage directly
through substrate inhibitors pending results from ongoing preclinical/clinical studies seeking
disease-modifying capabilities across NPD subtypes. Multi ‘omics may elucidate lysosomal
pathways amenable to modulation. Palliative symptom management still plays an essential
role in quality of life optimization.
Niemann-Pick disease (NPD) encompasses a group of autosomal recessive lipid storage
disorders arising from defective lysosomal acid sphingomyelinase (ASM) enzyme function,
impacting sphingomyelin metabolism and intracellular trafficking. Two major forms exist -
types A and B - distinguished by age of onset and visceral/neurological involvement severity.
Type A presents in infancy as a rapidly progressive, fatal neurological phenotype affecting
the lungs, liver and spleen. Type B has later childhood or adult onset with variable
progression.
Both arise from impaired sphingolipid catabolism building up in lysosomes. However,
mechanisms linking storage defects to tissue-specific manifestations remain unclear. While
hematopoietic stem cell transplantation shows potential benefits for Type B, no curative
treatments exist. This review surveys sphingomyelin biology, clinical features of NPD types,
the ASM gene/protein defective across subtypes, current management strategies and
emerging therapies targeting neurodegeneration outcomes through enzyme supplementation
or gene therapy aiming to reduce storage and clear accumulated substrates.
Sphingolipid Metabolism and Function
Sphingolipids including sphingomyelin represent an essential class of membrane
glycerophospholipids regulated by lysosomal catabolism:
- Biosynthesis involves serine palmitoyltransferase generating sphingoid long-chain bases,
followed by acylation to dihydroceramide then ceramide/sphingomyelin synthesis.
- Key sphingolipids act as second messengers/signaling molecules regulating proliferation,
apoptosis and autophagy through ceramide/sphingosine-1-phosphate rheostasis.
- Lysosomal ceramidase and acid sphingomyelinase hydrolyze complex sphingolipids,
ceramide and sphingomyelin for normal turnover.
- Sphingomyelin composes ~15% of brain myelin sheaths regulating neuronal integrity,
highlighting neurodegeneration consequences in NPD.
Defective ASM or redundancy pathways impairing substrate catabolism lead to storage,
compromising membrane organization and signaling networks driving disease
pathophysiology.
Clinical Features of NPD
Specific clinical features depend on neuron involvement severity:
NPD Type A
- Macrocrania, hepatosplenomegaly, vomiting, failure to thrive in infants.
- Rapidly progressive neurodegeneration, seizures, dysphagia and death by ages 2-3 without
transplantation.
NPD Type B
- Hepatosplenomegaly, vomiting initially, then varied outcomes.
- Late onset neurological signs - ataxia, dysarthria, seizures, dementia.
- Non-neurological signs - pulmonary disease, bone abnormalities.
Niemann-Pick C (NPC) Disorders
- Variable and multisystemic features based onNPC1/NPC2 gene defects.
- Hepatosplenomegaly, neurological findings, pulmonary/endocrine involvement.
Overall, brain macrophages/microglia accumulate sphingomyelin leading to
neurodegeneration severity differences dependent upon precise variants and residual enzyme
activity levels.
Genetics of NPD
All forms arise from defects in ASM (SMPD1), which encodes the lysosomal acid
sphingomyelinase enzyme:
- NPD Type A/B - Biallelic loss-of-function mutations in SMPD1 preventing sufficient ASM
levels.
- NPD Type A pseudo-deficiency - Homozygosity for splicing or missense variants
conferring residual activity.
Genotype-phenotype correlations link residual ASM amounts to severity, though variants
may not fully predict outcomes. Heterozygotes usually show no signs. Carrier testing of
relatives assesses risks.
Diagnosis
Typically based upon:
- Clinical suspicion from hepatosplenomegaly, neurological deterioration, bone
abnormalities.
- Enzyme activity assays on leukocytes/fibroblasts confirming <5% ASM activity.
- Genetic testing identifies biallelic SMPD1 variants establishing molecular diagnosis.
- MRI/CT reveals hepatic/spleen enlargement, brain atrophy in neurological cases.
- Sphingomyelin accumulation on tissue biopsy visualized histologically via filipin staining.
Early diagnosis guides screening family members and developing newborn screening
algorithms. Differential diagnosis excludes Gaucher’s disease.
Disease Management
No cure exists; care focuses reducing complications:
- Supportive care addresses pneumonias, poor nutrition in Type A.
- Seizure control utilizes anticonvulsants addressing neurological deterioration.
- Symptomatic care manages bone pain, movement disorders.
- Hematopoietic stem cell transplantation shows potential benefits for Type B.
- Substrate reduction therapies addressGSL storage defects in NPC variants.
- Enzyme replacement trials evaluate ASM supplementation or gene therapy concepts in
animal models.
Future perspectives
Progress targets neuroprotection through tailoring hematopoietic cell therapies, AAV-
delivered gene therapies replacing deficient ASM more broadly or addressing storage directly
through substrate inhibitors pending results from ongoing preclinical/clinical studies seeking
disease-modifying capabilities across NPD subtypes. Multi ‘omics may elucidate lysosomal
pathways amenable to modulation. Palliative symptom management still plays an essential
role in quality of life optimization.
Niemann-Pick disease (NPD) encompasses a group of autosomal recessive lipid storage
disorders arising from defective lysosomal acid sphingomyelinase (ASM) enzyme function,
impacting sphingomyelin metabolism and intracellular trafficking. Two major forms exist -
types A and B - distinguished by age of onset and visceral/neurological involvement severity.
Type A presents in infancy as a rapidly progressive, fatal neurological phenotype affecting
the lungs, liver and spleen. Type B has later childhood or adult onset with variable
progression.
Both arise from impaired sphingolipid catabolism building up in lysosomes. However,
mechanisms linking storage defects to tissue-specific manifestations remain unclear. While
hematopoietic stem cell transplantation shows potential benefits for Type B, no curative
treatments exist. This review surveys sphingomyelin biology, clinical features of NPD types,
the ASM gene/protein defective across subtypes, current management strategies and
emerging therapies targeting neurodegeneration outcomes through enzyme supplementation
or gene therapy aiming to reduce storage and clear accumulated substrates.
Sphingolipid Metabolism and Function
Sphingolipids including sphingomyelin represent an essential class of membrane
glycerophospholipids regulated by lysosomal catabolism:
- Biosynthesis involves serine palmitoyltransferase generating sphingoid long-chain bases,
followed by acylation to dihydroceramide then ceramide/sphingomyelin synthesis.
- Key sphingolipids act as second messengers/signaling molecules regulating proliferation,
apoptosis and autophagy through ceramide/sphingosine-1-phosphate rheostasis.
- Lysosomal ceramidase and acid sphingomyelinase hydrolyze complex sphingolipids,
ceramide and sphingomyelin for normal turnover.
- Sphingomyelin composes ~15% of brain myelin sheaths regulating neuronal integrity,
highlighting neurodegeneration consequences in NPD.
Defective ASM or redundancy pathways impairing substrate catabolism lead to storage,
compromising membrane organization and signaling networks driving disease
pathophysiology.
Clinical Features of NPD
Specific clinical features depend on neuron involvement severity:
NPD Type A
- Macrocrania, hepatosplenomegaly, vomiting, failure to thrive in infants.
- Rapidly progressive neurodegeneration, seizures, dysphagia and death by ages 2-3 without
transplantation.
NPD Type B
- Hepatosplenomegaly, vomiting initially, then varied outcomes.
- Late onset neurological signs - ataxia, dysarthria, seizures, dementia.
- Non-neurological signs - pulmonary disease, bone abnormalities.
Niemann-Pick C (NPC) Disorders
- Variable and multisystemic features based onNPC1/NPC2 gene defects.
- Hepatosplenomegaly, neurological findings, pulmonary/endocrine involvement.
Overall, brain macrophages/microglia accumulate sphingomyelin leading to
neurodegeneration severity differences dependent upon precise variants and residual enzyme
activity levels.
Genetics of NPD
All forms arise from defects in ASM (SMPD1), which encodes the lysosomal acid
sphingomyelinase enzyme:
- NPD Type A/B - Biallelic loss-of-function mutations in SMPD1 preventing sufficient ASM
levels.
- NPD Type A pseudo-deficiency - Homozygosity for splicing or missense variants
conferring residual activity.
Genotype-phenotype correlations link residual ASM amounts to severity, though variants
may not fully predict outcomes. Heterozygotes usually show no signs. Carrier testing of
relatives assesses risks.
Diagnosis
Typically based upon:
- Clinical suspicion from hepatosplenomegaly, neurological deterioration, bone
abnormalities.
- Enzyme activity assays on leukocytes/fibroblasts confirming <5% ASM activity.
- Genetic testing identifies biallelic SMPD1 variants establishing molecular diagnosis.
- MRI/CT reveals hepatic/spleen enlargement, brain atrophy in neurological cases.
- Sphingomyelin accumulation on tissue biopsy visualized histologically via filipin staining.
Early diagnosis guides screening family members and developing newborn screening
algorithms. Differential diagnosis excludes Gaucher’s disease.
Disease Management
No cure exists; care focuses reducing complications:
- Supportive care addresses pneumonias, poor nutrition in Type A.
- Seizure control utilizes anticonvulsants addressing neurological deterioration.
- Symptomatic care manages bone pain, movement disorders.
- Hematopoietic stem cell transplantation shows potential benefits for Type B.
- Substrate reduction therapies addressGSL storage defects in NPC variants.
- Enzyme replacement trials evaluate ASM supplementation or gene therapy concepts in
animal models.
Future perspectives
Progress targets neuroprotection through tailoring hematopoietic cell therapies, AAV-
delivered gene therapies replacing deficient ASM more broadly or addressing storage directly
through substrate inhibitors pending results from ongoing preclinical/clinical studies seeking
disease-modifying capabilities across NPD subtypes. Multi ‘omics may elucidate lysosomal
pathways amenable to modulation. Palliative symptom management still plays an essential
role in quality of life optimization.
Niemann-Pick disease (NPD) encompasses a group of autosomal recessive lipid storage
disorders arising from defective lysosomal acid sphingomyelinase (ASM) enzyme function,
impacting sphingomyelin metabolism and intracellular trafficking. Two major forms exist -
types A and B - distinguished by age of onset and visceral/neurological involvement severity.
Type A presents in infancy as a rapidly progressive, fatal neurological phenotype affecting
the lungs, liver and spleen. Type B has later childhood or adult onset with variable
progression.
Both arise from impaired sphingolipid catabolism building up in lysosomes. However,
mechanisms linking storage defects to tissue-specific manifestations remain unclear. While
hematopoietic stem cell transplantation shows potential benefits for Type B, no curative
treatments exist. This review surveys sphingomyelin biology, clinical features of NPD types,
the ASM gene/protein defective across subtypes, current management strategies and
emerging therapies targeting neurodegeneration outcomes through enzyme supplementation
or gene therapy aiming to reduce storage and clear accumulated substrates.
Sphingolipid Metabolism and Function
Sphingolipids including sphingomyelin represent an essential class of membrane
glycerophospholipids regulated by lysosomal catabolism:
- Biosynthesis involves serine palmitoyltransferase generating sphingoid long-chain bases,
followed by acylation to dihydroceramide then ceramide/sphingomyelin synthesis.
- Key sphingolipids act as second messengers/signaling molecules regulating proliferation,
apoptosis and autophagy through ceramide/sphingosine-1-phosphate rheostasis.
- Lysosomal ceramidase and acid sphingomyelinase hydrolyze complex sphingolipids,
ceramide and sphingomyelin for normal turnover.
- Sphingomyelin composes ~15% of brain myelin sheaths regulating neuronal integrity,
highlighting neurodegeneration consequences in NPD.
Defective ASM or redundancy pathways impairing substrate catabolism lead to storage,
compromising membrane organization and signaling networks driving disease
pathophysiology.
Clinical Features of NPD
Specific clinical features depend on neuron involvement severity:
NPD Type A
- Macrocrania, hepatosplenomegaly, vomiting, failure to thrive in infants.
- Rapidly progressive neurodegeneration, seizures, dysphagia and death by ages 2-3 without
transplantation.
NPD Type B
- Hepatosplenomegaly, vomiting initially, then varied outcomes.
- Late onset neurological signs - ataxia, dysarthria, seizures, dementia.
- Non-neurological signs - pulmonary disease, bone abnormalities.
Niemann-Pick C (NPC) Disorders
- Variable and multisystemic features based onNPC1/NPC2 gene defects.
- Hepatosplenomegaly, neurological findings, pulmonary/endocrine involvement.
Overall, brain macrophages/microglia accumulate sphingomyelin leading to
neurodegeneration severity differences dependent upon precise variants and residual enzyme
activity levels.
Genetics of NPD
All forms arise from defects in ASM (SMPD1), which encodes the lysosomal acid
sphingomyelinase enzyme:
- NPD Type A/B - Biallelic loss-of-function mutations in SMPD1 preventing sufficient ASM
levels.
- NPD Type A pseudo-deficiency - Homozygosity for splicing or missense variants
conferring residual activity.
Genotype-phenotype correlations link residual ASM amounts to severity, though variants
may not fully predict outcomes. Heterozygotes usually show no signs. Carrier testing of
relatives assesses risks.
Diagnosis
Typically based upon:
- Clinical suspicion from hepatosplenomegaly, neurological deterioration, bone
abnormalities.
- Enzyme activity assays on leukocytes/fibroblasts confirming <5% ASM activity.
- Genetic testing identifies biallelic SMPD1 variants establishing molecular diagnosis.
- MRI/CT reveals hepatic/spleen enlargement, brain atrophy in neurological cases.
- Sphingomyelin accumulation on tissue biopsy visualized histologically via filipin staining.
Early diagnosis guides screening family members and developing newborn screening
algorithms. Differential diagnosis excludes Gaucher’s disease.
Disease Management
No cure exists; care focuses reducing complications:
- Supportive care addresses pneumonias, poor nutrition in Type A.
- Seizure control utilizes anticonvulsants addressing neurological deterioration.
- Symptomatic care manages bone pain, movement disorders.
- Hematopoietic stem cell transplantation shows potential benefits for Type B.
- Substrate reduction therapies addressGSL storage defects in NPC variants.
- Enzyme replacement trials evaluate ASM supplementation or gene therapy concepts in
animal models.
Future perspectives
Progress targets neuroprotection through tailoring hematopoietic cell therapies, AAV-
delivered gene therapies replacing deficient ASM more broadly or addressing storage directly
through substrate inhibitors pending results from ongoing preclinical/clinical studies seeking
disease-modifying capabilities across NPD subtypes. Multi ‘omics may elucidate lysosomal
pathways amenable to modulation. Palliative symptom management still plays an essential
role in quality of life optimization.
Niemann-Pick disease (NPD) encompasses a group of autosomal recessive lipid storage
disorders arising from defective lysosomal acid sphingomyelinase (ASM) enzyme function,
impacting sphingomyelin metabolism and intracellular trafficking. Two major forms exist -
types A and B - distinguished by age of onset and visceral/neurological involvement severity.
Type A presents in infancy as a rapidly progressive, fatal neurological phenotype affecting
the lungs, liver and spleen. Type B has later childhood or adult onset with variable
progression.
Both arise from impaired sphingolipid catabolism building up in lysosomes. However,
mechanisms linking storage defects to tissue-specific manifestations remain unclear. While
hematopoietic stem cell transplantation shows potential benefits for Type B, no curative
treatments exist. This review surveys sphingomyelin biology, clinical features of NPD types,
the ASM gene/protein defective across subtypes, current management strategies and
emerging therapies targeting neurodegeneration outcomes through enzyme supplementation
or gene therapy aiming to reduce storage and clear accumulated substrates.
Sphingolipid Metabolism and Function
Sphingolipids including sphingomyelin represent an essential class of membrane
glycerophospholipids regulated by lysosomal catabolism:
- Biosynthesis involves serine palmitoyltransferase generating sphingoid long-chain bases,
followed by acylation to dihydroceramide then ceramide/sphingomyelin synthesis.
- Key sphingolipids act as second messengers/signaling molecules regulating proliferation,
apoptosis and autophagy through ceramide/sphingosine-1-phosphate rheostasis.
- Lysosomal ceramidase and acid sphingomyelinase hydrolyze complex sphingolipids,
ceramide and sphingomyelin for normal turnover.
- Sphingomyelin composes ~15% of brain myelin sheaths regulating neuronal integrity,
highlighting neurodegeneration consequences in NPD.
Defective ASM or redundancy pathways impairing substrate catabolism lead to storage,
compromising membrane organization and signaling networks driving disease
pathophysiology.
Clinical Features of NPD
Specific clinical features depend on neuron involvement severity:
NPD Type A
- Macrocrania, hepatosplenomegaly, vomiting, failure to thrive in infants.
- Rapidly progressive neurodegeneration, seizures, dysphagia and death by ages 2-3 without
transplantation.
NPD Type B
- Hepatosplenomegaly, vomiting initially, then varied outcomes.
- Late onset neurological signs - ataxia, dysarthria, seizures, dementia.
- Non-neurological signs - pulmonary disease, bone abnormalities.
Niemann-Pick C (NPC) Disorders
- Variable and multisystemic features based onNPC1/NPC2 gene defects.
- Hepatosplenomegaly, neurological findings, pulmonary/endocrine involvement.
Overall, brain macrophages/microglia accumulate sphingomyelin leading to
neurodegeneration severity differences dependent upon precise variants and residual enzyme
activity levels.
Genetics of NPD
All forms arise from defects in ASM (SMPD1), which encodes the lysosomal acid
sphingomyelinase enzyme:
- NPD Type A/B - Biallelic loss-of-function mutations in SMPD1 preventing sufficient ASM
levels.
- NPD Type A pseudo-deficiency - Homozygosity for splicing or missense variants
conferring residual activity.
Genotype-phenotype correlations link residual ASM amounts to severity, though variants
may not fully predict outcomes. Heterozygotes usually show no signs. Carrier testing of
relatives assesses risks.
Diagnosis
Typically based upon:
- Clinical suspicion from hepatosplenomegaly, neurological deterioration, bone
abnormalities.
- Enzyme activity assays on leukocytes/fibroblasts confirming <5% ASM activity.
- Genetic testing identifies biallelic SMPD1 variants establishing molecular diagnosis.
- MRI/CT reveals hepatic/spleen enlargement, brain atrophy in neurological cases.
- Sphingomyelin accumulation on tissue biopsy visualized histologically via filipin staining.
Early diagnosis guides screening family members and developing newborn screening
algorithms. Differential diagnosis excludes Gaucher’s disease.
Disease Management
No cure exists; care focuses reducing complications:
- Supportive care addresses pneumonias, poor nutrition in Type A.
- Seizure control utilizes anticonvulsants addressing neurological deterioration.
- Symptomatic care manages bone pain, movement disorders.
- Hematopoietic stem cell transplantation shows potential benefits for Type B.
- Substrate reduction therapies addressGSL storage defects in NPC variants.
- Enzyme replacement trials evaluate ASM supplementation or gene therapy concepts in
animal models.
Future perspectives
Progress targets neuroprotection through tailoring hematopoietic cell therapies, AAV-
delivered gene therapies replacing deficient ASM more broadly or addressing storage directly
through substrate inhibitors pending results from ongoing preclinical/clinical studies seeking
disease-modifying capabilities across NPD subtypes. Multi ‘omics may elucidate lysosomal
pathways amenable to modulation. Palliative symptom management still plays an essential
role in quality of life optimization.
Niemann-Pick disease (NPD) encompasses a group of autosomal recessive lipid storage
disorders arising from defective lysosomal acid sphingomyelinase (ASM) enzyme function,
impacting sphingomyelin metabolism and intracellular trafficking. Two major forms exist -
types A and B - distinguished by age of onset and visceral/neurological involvement severity.
Type A presents in infancy as a rapidly progressive, fatal neurological phenotype affecting
the lungs, liver and spleen. Type B has later childhood or adult onset with variable
progression.
Both arise from impaired sphingolipid catabolism building up in lysosomes. However,
mechanisms linking storage defects to tissue-specific manifestations remain unclear. While
hematopoietic stem cell transplantation shows potential benefits for Type B, no curative
treatments exist. This review surveys sphingomyelin biology, clinical features of NPD types,
the ASM gene/protein defective across subtypes, current management strategies and
emerging therapies targeting neurodegeneration outcomes through enzyme supplementation
or gene therapy aiming to reduce storage and clear accumulated substrates.
Sphingolipid Metabolism and Function
Sphingolipids including sphingomyelin represent an essential class of membrane
glycerophospholipids regulated by lysosomal catabolism:
- Biosynthesis involves serine palmitoyltransferase generating sphingoid long-chain bases,
followed by acylation to dihydroceramide then ceramide/sphingomyelin synthesis.
- Key sphingolipids act as second messengers/signaling molecules regulating proliferation,
apoptosis and autophagy through ceramide/sphingosine-1-phosphate rheostasis.
- Lysosomal ceramidase and acid sphingomyelinase hydrolyze complex sphingolipids,
ceramide and sphingomyelin for normal turnover.
- Sphingomyelin composes ~15% of brain myelin sheaths regulating neuronal integrity,
highlighting neurodegeneration consequences in NPD.
Defective ASM or redundancy pathways impairing substrate catabolism lead to storage,
compromising membrane organization and signaling networks driving disease
pathophysiology.
Clinical Features of NPD
Specific clinical features depend on neuron involvement severity:
NPD Type A
- Macrocrania, hepatosplenomegaly, vomiting, failure to thrive in infants.
- Rapidly progressive neurodegeneration, seizures, dysphagia and death by ages 2-3 without
transplantation.
NPD Type B
- Hepatosplenomegaly, vomiting initially, then varied outcomes.
- Late onset neurological signs - ataxia, dysarthria, seizures, dementia.
- Non-neurological signs - pulmonary disease, bone abnormalities.
Niemann-Pick C (NPC) Disorders
- Variable and multisystemic features based onNPC1/NPC2 gene defects.
- Hepatosplenomegaly, neurological findings, pulmonary/endocrine involvement.
Overall, brain macrophages/microglia accumulate sphingomyelin leading to
neurodegeneration severity differences dependent upon precise variants and residual enzyme
activity levels.
Genetics of NPD
All forms arise from defects in ASM (SMPD1), which encodes the lysosomal acid
sphingomyelinase enzyme:
- NPD Type A/B - Biallelic loss-of-function mutations in SMPD1 preventing sufficient ASM
levels.
- NPD Type A pseudo-deficiency - Homozygosity for splicing or missense variants
conferring residual activity.
Genotype-phenotype correlations link residual ASM amounts to severity, though variants
may not fully predict outcomes. Heterozygotes usually show no signs. Carrier testing of
relatives assesses risks.
Diagnosis
Typically based upon:
- Clinical suspicion from hepatosplenomegaly, neurological deterioration, bone
abnormalities.
- Enzyme activity assays on leukocytes/fibroblasts confirming <5% ASM activity.
- Genetic testing identifies biallelic SMPD1 variants establishing molecular diagnosis.
- MRI/CT reveals hepatic/spleen enlargement, brain atrophy in neurological cases.
- Sphingomyelin accumulation on tissue biopsy visualized histologically via filipin staining.
Early diagnosis guides screening family members and developing newborn screening
algorithms. Differential diagnosis excludes Gaucher’s disease.
Disease Management
No cure exists; care focuses reducing complications:
- Supportive care addresses pneumonias, poor nutrition in Type A.
- Seizure control utilizes anticonvulsants addressing neurological deterioration.
- Symptomatic care manages bone pain, movement disorders.
- Hematopoietic stem cell transplantation shows potential benefits for Type B.
- Substrate reduction therapies addressGSL storage defects in NPC variants.
- Enzyme replacement trials evaluate ASM supplementation or gene therapy concepts in
animal models.
Future perspectives
Progress targets neuroprotection through tailoring hematopoietic cell therapies, AAV-
delivered gene therapies replacing deficient ASM more broadly or addressing storage directly
through substrate inhibitors pending results from ongoing preclinical/clinical studies seeking
disease-modifying capabilities across NPD subtypes. Multi ‘omics may elucidate lysosomal
pathways amenable to modulation. Palliative symptom management still plays an essential
role in quality of life optimization.
